Form 4: Eli Lilly Director Acquires Shares Through Deferral Plan

Director Ralph Alvarez acquired 15 shares of Eli Lilly common stock through a deferral plan, as reported in a recent SEC filing.

Summary

• Ralph Alvarez, a director at Eli Lilly & Co, acquired 15 shares of common stock on May 20, 2024.
• The shares were acquired at a price of $783.18 per share.
• This transaction was part of the Lilly Directors' Deferral Plan, where the shares are deferred in lieu of cash compensation.
• The shares will be settled in common stock after Mr. Alvarez's separation from service.
• Following this transaction, Mr. Alvarez beneficially owns 54,044 shares of Eli Lilly common stock.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it shows director alignment with company performance. There is no indication of any negative sentiment.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The acquired shares will be settled in common stock following the reporting person's separation from service.

Industry Context

This is a routine filing related to director compensation and is common practice for publicly traded companies.

Comparison to Industry Standards

• Director share acquisitions through deferral plans are a common practice among large publicly traded companies, such as those in the pharmaceutical sector like Pfizer (PFE) and Johnson & Johnson (JNJ).
• These plans are often used to align the interests of directors with those of shareholders.
• The specific terms of deferral and settlement may vary, but the general structure is similar across many companies.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it shows director confidence in the company.

Key Dates

Keywords

Eli Lilly, Director, Share Acquisition, Deferral Plan, SEC Form 4, LLY, Stock Units, Beneficial Ownership